China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China
· Delayed Price · Currency is CNY 17.96
+0.08 (0.45%)
Apr 29, 2026, 3:00 PM CST
SHA:600062 Revenue
China Resources Double-Crane Pharmaceutical had revenue of 2.81B CNY in the quarter ending March 31, 2026, a decrease of -8.84%. This brings the company's revenue in the last twelve months to 10.73B, down -3.74% year-over-year. In the year 2025, China Resources Double-Crane Pharmaceutical had annual revenue of 11.00B, down -1.88%.
Revenue (ttm)
10.73B
Revenue Growth
-3.74%
P/S Ratio
1.73
Revenue / Employee
813.76K
Employees
13,184
Market Cap
18.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.00B | -210.83M | -1.88% |
| Dec 31, 2024 | 11.21B | -98.52M | -0.87% |
| Dec 31, 2023 | 11.31B | 1.68B | 17.50% |
| Dec 31, 2022 | 9.63B | 513.80M | 5.64% |
| Dec 31, 2021 | 9.11B | 607.58M | 7.14% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tonghua Dongbao Pharmaceutical | 2.95B |
| Fujian Cosunter Pharmaceutical | 430.98M |
| Walvax Biotechnology | 2.42B |
| Hybio Pharmaceutical | 898.10M |
| Joincare Pharmaceutical Group Industry | 14.85B |
| Wanbangde Pharmaceutical Holding Group | 1.14B |
| China Resources Jiangzhong Pharmaceutical Co.,Ltd | 4.07B |
| Shandong Buchang Pharmaceuticals | 10.96B |